A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer (SO2)
A Pilot Study Utilizing Proteomic and Genomic Profiling by Reverse Phase Protein Microarray (RPMA), IHC Analysis, RNA Seq, and Exome Sequencing of Patients' Tumors to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer
Sponsor: Side-Out Foundation
A NA clinical study on Metastatic Breast Cancer, this trial is completed. The trial is conducted by Side-Out Foundation and has accumulated 9 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Apr 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Apr 2023 [monthly]
Completed NA
-
May 2022 — Dec 2022 [monthly]
Completed NA
▶ Show 4 earlier versions
-
Jan 2021 — May 2022 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
May 2018 — Jun 2018 [monthly]
Completed NA
-
Jan 2017 — May 2018 [monthly]
Completed NA
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Side-Out Foundation
- Translational Drug Development
For direct contact, visit the study record on ClinicalTrials.gov .